Eloxx Pharmaceuticals, Inc. (ELOX) News
Filter ELOX News Items
ELOX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ELOX News Highlights
- 500 - Internal server error
- Over the past 6 days, the trend for ELOX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ELOX are CF.
Latest ELOX News From Around the Web
Below are the latest news stories about Eloxx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELOX as an investment opportunity.
Here's What Eloxx Pharmaceuticals, Inc.'s (NASDAQ:ELOX) Shareholder Ownership Structure Looks LikeA look at the shareholders of Eloxx Pharmaceuticals, Inc. ( NASDAQ:ELOX ) can tell us which group is most powerful... |
Eloxx Pharma Sees Data Readout From First Four Arms Of Cystic Fibrosis Study By End Of 2021Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) provided an enrollment update for the ongoing Phase 2 trial of ELX-02 to treat cystic fibrosis (CF) in patients with at least one G542X allele. Based on enrollment to date, Eloxx expects to present data from the first four treatment arms in Q4 of 2021. As of the end of June 2021, Eloxx has enrolled a sufficient number of patients to assess the biological activity of ELX-02. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense |
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic FibrosisData Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele. Based on enrollment to date, Eloxx expects to present data from the first four treatment arms of the study in the fourth quarter of this yea |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWelcome back, traders, and good morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe've got one more day of trading left in the week and we're starting it off with the biggest-pre-market stock movers for Friday! |
Are Options Traders Betting on a Big Move in Eloxx Pharmaceuticals (ELOX) Stock?Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately. |
Is the Options Market Predicting a Spike in Eloxx (ELOX) Stock?Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately. |
Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional SharesWALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the closing of an underwritten public offering of 38,333,334 shares of common stock at a public offering price of $1.35 per share. The closing included the full exercise of the underwriters’ option to purchase an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Aggregate gross proceeds from the offering were approximately $51.75 million, before deducting underwriting discounts and commissions and offering expenses. B. Riley Securities, Inc. is acting as sole-book running manager for the offering. A shelf registration stateme... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers onWe're getting you ready for the last day of trading this week with a look at the biggest pre-market stock movers for Friday! |
Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockWALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the pricing of an underwritten public offering of 33,333,334 shares of common stock at a public offering price of $1.35 per share. In addition, the Company expects to grant the underwriters a 30-day option to purchase an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. B. Riley Securities, Inc. is acting as sole-book running manager for the offering. The offering is expected to close on or about May 18, 2021, subject to customary closing conditions. The common stock is being offered pursuant to a shelf registration statement... |